Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Recently, anti-PD-1 antibodies plus lenvatinib has been administered in a series of solid tumors. Yet, the efficacy of chemo-free treatment of this combined therapy has seldom been reported in gallbladder cancer (GBC). The aim of our study was to initially evaluate the efficacy of the chemo-free treatment in unresectable GBCs.
Methods: We retrospectively collected the clinical data of unresectable GBCs treated using chemo-free anti-PD-1 antibodies plus lenvatinib in our hospital from March 2019 to August 2022. The clinical responses were assessed, and PD-1 expression was evaluated.
Results: Our study enrolled 52 patients, with the median progression-free survival being 7.0 months and the median overall survival being 12.0 months. The objective response rate was 46.2% and the disease control rate was 65.4%. The expression of PD-L1 in patients with objective response was significantly higher than those with progression of disease.
Conclusions: For patients with unresectable GBC, when not eligible for systemic chemotherapy, chemo-free treatment using anti-PD-1 antibodies with lenvatinib may become a safe and rational choice. The expression of PD-L1 in tumor tissues may be correlated to the objective response, and thus is expected to be a predictor of efficacy, and further clinical studies are certainly needed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252738 | PMC |
| http://dx.doi.org/10.3390/diagnostics13111833 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Towards a chemo-free approach for follicular lymphoma.
Br J Haematol
August 2025
Division of Hematology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy.
The therapeutic landscape of follicular lymphoma (FL) is undergoing a transformative shift driven by the advent of novel chemo-free strategies that challenge the traditional chemo-oriented paradigms; this shift offers promising alternatives for both newly diagnosed and relapsed or refractory (RR) patients. Available data support a full chemo-free approach starting from second-line therapy, with rituximab-lenalidomide (R2) or tafasitamab-R2, whereas bispecific antibodies (bsAbs), Bruton's tyrosine kinase (BTK) inhibitors and chimeric antigen receptor (CAR) T-cell therapies are available options after second relapse. In the near future, bsAbs, mainly in combination with lenalidomide, will likely be employed as first- or second-line therapy, potentially fully replacing immunochemotherapy, whereas CAR T-cell therapy will play a role in selected high-risk patients.
View Article and Find Full Text PDFThe MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.
BMC Cancer
August 2025
Department of Medicine, III - University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany.
Background: Mantle cell lymphoma (MCL) is a rare B-cell Non-Hodgkin-lymphoma that predominantly affects elderly patients. While younger and fit patients receive an intensive first-line treatment, older or comorbid patients have limited options of chemo-immunotherapy (CIT) alone followed by anti-CD20-antibody maintenance. Targeted oral agents as Bruton`s tyrosine kinase inhibitors (BTKi, e.
View Article and Find Full Text PDFChemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review.
Immunotherapy
June 2025
Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
B-lymphoid/myeloid mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia that most likely originates from hematopoietic pluripotent stem cells. It is a heterogeneous group of leukemia characterized by the expression of more than 1 specific marker from each hematopoietic lineage (lymphoid and myeloid-specific antigens). The MLL-AF4 fusion gene is a common genetic abnormality in MPAL.
View Article and Find Full Text PDFMantle cell lymphoma: how to clarify the confusion around first-line treatment?
Curr Opin Oncol
September 2025
Université de Paris Cité, Institut Imagine , Laboratory of Hematological Disorders, INSERM UMR1163, Paris, France.
Purpose Of Review: First-line treatment strategies for mantle cell lymphoma (MCL) have greatly improved in recent years. High dose cytarabine, autologous stem cell transplantation for eligible patients and anti-CD20 maintenance therapy for all patients, have contributed to enhanced results, establishing a standard of care with unprecedented long-term outcome. Recently, a growing number of effective options such as Bruton's tyrosine kinase (BTK) inhibitors, combinations of targeted therapies, and immunotherapies, have emerged, leading to confusion regarding the optimal first-line approach.
View Article and Find Full Text PDFManagement of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in a Jehovah's Witness using chemotherapy free regimen: A case report and review of literature.
Leuk Res Rep
June 2025
Division of Hematology and Cellular Therapy, Allegheny Health Cancer Institute, Pittsburgh, PA, USA.
Introduction And Importance: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (pH-positive ALL) in Jehovah's Witness (JW) using chemotherapy agents, opens an ethically and morally challenging paradigm instead of their religious practices.
Case Presentation: We present a case of pH-positive B cell ALL in a Jehovah's Witness patient who refused the transfusion of blood as a part of their treatment regimen. We intended to treat this patient using a new "chemotherapy-free" approach and achieved Minimal Residual Disease (MRD) negative state with durable outcomes for the next three years.